The hypoglycemic metabolites and potential mechanisms of Lilium lancifolium (Juandan lily)
Frontiers in Pharmacology · 08.06.2026 · 17
DOI: 10.3389/fphar.2026.1806579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.06.2026. Verfasst von Qinxuan Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics, Changsha Medical University, Changsha, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In Chinese folk medicine, lily bulbs have traditionally been used to help lower blood glucose levels. Numerous studies have demonstrated that extracts from lily bulbs possess significant hypoglycemic activity. However, the specific active metabolites and their underlying mechanisms remain unclear. This study first evaluated the hypoglycemic activities of extracts from four common lily species: Lilium lancifolium Thunb ( Juandan lily), Lilium davidii var. Unicolor ( Lanzhou lily), Lilium brownii var. Viridulum ( Longya lily), and Guiyanghong lily. The findings revealed that Juandan lily extract exhibited the most potent hypoglycemic activity. Subsequently, UPLC-Q-TOF-MS analysis was employed to profile the major metabolites of Juandan lily, resulting in the identification of 25 high-abundance metabolites. These included 8 regalosides, 5 flavonoids, 4 dioscin-type saponins, 5 phenylpropanoids, and 3 other types of metabolites. Notably, six of them were reported for the first time in lilies. To further investigate the hypoglycemic metabolites, three high-content metabolites (caffeic acid, regaloside A, and regaloside B) from Juandan lily were subjected to hypoglycemic activity assessment. The results indicated that both regaloside A and regaloside B possessed significant hypoglycemic activity, with regaloside B demonstrating the strongest effect, reducing blood glucose levels in hyperglycemic model mice from an initial values of 27.87 ± 0.67 mmol/L to 14.11 ± 1.09 mmol/L. Furthermore, regaloside A and B were found to inhibit postprandial blood glucose elevation in mice, with an efficacy comparable to that of the positive control drug. This effect was attributed to the inhibition of α-glucosidase activity. Molecular docking studies revealed that regaloside A and B could bind to α-glucosidase (including maltase-glucoamylase and sucrase-isomaltase). These interactions may inhibit the α-glucosidase activity and contribute to the observed hypoglycemic effect. This study elucidates the active metabolites and the potential mechanism underlying the hypoglycemic activity of lily bulbs for the first time, thereby providing a foundation for the development of novel hypoglycemic agents and the high-value utilization of lily resources.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics, Changsha Medical University, Changsha, China.
- Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China.
- Yuelushan Laboratory, Changsha, China.
Zitieren
APA
Wu, Q., Xiao, K., Zhao, D., Tang, R., Liu, W., Li, F., Wang, H., & Chen, F. (2026). The hypoglycemic metabolites and potential mechanisms of Lilium lancifolium (Juandan lily). Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1806579
Vancouver
Wu Q, Xiao K, Zhao D, Tang R, Liu W, Li F, et al. The hypoglycemic metabolites and potential mechanisms of Lilium lancifolium (Juandan lily). Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1806579
BibTeX
@article{Wu2026,
author = {Wu, Qinxuan and Xiao, Kunyu and Zhao, Di and Tang, Rui and Liu, Weiping and Li, Feng and Wang, Hexiang and Chen, Fengming},
title = {The hypoglycemic metabolites and potential mechanisms of Lilium lancifolium (Juandan lily)},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1806579}
}
EUVIMED